Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND Cognitive impairment in schizophrenia is disabling, but current treatment options remain limited. OBJECTIVE To meta-analyze the efficacy and safety of adjunctive antidepressants for cognitive impairment in schizophrenia. DATA SOURCES AND STUDY SELECTION PubMed, MEDLINE, PsycINFO, and Cochrane Library databases were searched until 12/2013 for randomized controlled trials comparing antidepressant augmentation of antipsychotics with placebo regarding effects on cognitive functioning in schizophrenia. DATA EXTRACTION Two authors independently extracted data. Standardized mean differences (SMDs) were calculated for continuous outcomes and risk ratios for categorical outcomes. SMDs of individual cognitive tests were pooled on a study level within domains (primary outcome) and across domains. When results were heterogeneous, random instead of fixed effects models were used. RESULTS We meta-analyzed 11 studies (duration = 8.7 ± 3.7 weeks) including 568 patients (mean age = 39.5 ± 6.9 years, males = 67.2%, illness duration = 12.5 ± 8.0 years). Antidepressants included mirtazapine (4 studies; n = 126), citalopram (2 studies; n = 231), fluvoxamine (1 study; n = 47), duloxetine (1 study; n = 40), mianserin (1 study; n = 30), bupropion (1 study; n = 61), and reboxetine (1 study; n = 33). Statistically significant, but clinically negligible, advantages were found for pooled antidepressants compared to placebo in executive function (Hedges' g = 0.17, p = 0.02) and a composite cognition score (Hedges' g = 0.095, p = 0.012). Depression improved with serotonergic antidepressants (p = 0.0009) and selective serotonin reuptake inhibitors (p = 0.009), but not with pooled antidepressants (p = 0.39). Sedation was more common with pooled antidepressants (p = 0.04). CONCLUSION Adjunctive antidepressants do not demonstrate clinically significant effects on cognition in schizophrenia patients, however, larger studies, preferably in euthymic schizophrenia patients and using full neurocognitive batteries, are needed to confirm this finding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999 · cited 3×
“independent, core symptom domain of schizophrenia that separately predicts long-term functional outcome and quality of life (Green et al., 2000; Keefe and Fenton, 2007; Kane and Lencz, 2008).”
BackgroundA Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes
Wykes, T., Huddy, V., Cellard, C., McGurk, S. R., & Czobor, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10060855 · Cited by 1,693
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422 · cited 1×
“Cognitive symptoms are highly disabling, having a strong correlation with functional outcome (Green et al., 2000; Green et al., 2004; Bowie et al., 2008; Bowie et al., 2010).”
BackgroundMechanisms of CaMKII action in long-term potentiation
Lisman, J., Yasuda, R., & Raghavachari, S. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3192 · Cited by 1,134 · cited 2×
“…cognitive dysfunction in schizophrenia is unclear, but glutamatergic, cholinergic, GABAergic, and histaminergic hypotheses have the most support (Abi-Dargham, 2004; Foster et al., 2012; Jones et al., 2012; Lisman et al., 2012; Miyamoto et al., 2012; Nakazawa et al., 2012; Vohora and Bhowmik, 2012).”
BackgroundNeurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130 · cited 4×
“, 2006; Kane and Lencz, 2008) and can be significant by the time of the first episode (Mesholam-Gately et al., 2009).”
BackgroundInfluentialGABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498 · cited 2×
“The exact mechanism of cognitive dysfunction in schizophrenia is unclear, but glutamatergic, cholinergic, GABAergic, and histaminergic hypotheses have the most support (Abi-Dargham, 2004; Lisman et al., 2012; Nakazawa et al., 2012; Miyamoto et al., 2012; Jones et al., 2012; Foster et al., 2010; Vohora & Bhowmik, 2012).”
BackgroundBuchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438 · cited 2×
“5 standard deviations below matched control subjects (Mohamed et al., 1999; Bilder et al., 2000; Velligan et al., 2000; Buchanan et al., 2005; Green, 2006; Zanelli et al., 2010).”
BackgroundInfluentialHow should DSM-V criteria for schizophrenia include cognitive impairment?
Keefe, R. S. E., & Fenton, W. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm046 · Cited by 394
Interventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304
Evins, A. E., Cather, C., Culhane, M. A., Birnbaum, A., Horowitz, J., Hsieh, E., Freudenreich, O., Henderson, D. C., Schoenfeld, D. A., Rigotti, N. A., et al. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0b013e3180ca86fa · Cited by 179 · cited 2×
“Data from five studies utilizing bupropion that tested cognition (George et al., 2002; Evins et al., 2005a,b; George et al., 2006; Evins et al., 2007; Culhane et al., 2008; George et al., 2008; Moss et al., 2009; Weiner et al., 2012) were not meta-analyzable as presented in the published papers and…”
MethodZisook, S., Kasckow, J. W., Lanouette, N. M., Golshan, S., Fellows, I., Vahia, I., Mohamed, S., & Rao, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05699gre · Cited by 45
Cited by
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 741
Correll, C. U., Rubio, J. M., Inczedy-Farkas, G., Birnbaum, M. L., Kane, J. M., & Leucht, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0624 · Cited by 214
Self-citationAn observational treatment study of metacognition in anxious-depression
Fox, C. A., Lee, C. T., Hanlon, A. K., Seow, T. X., Lynch, K., Harty, S., Richards, D., Palacios, J., O'Keane, V., Stephan, K. E., et al. (2023) · eLife · doi:10.7554/elife.87193.3 · Cited by 1
“However, studies examining the impact of antidepressants on cognition have typically focused on cognitive capacities other than metacognition (Prado et al., 2018; Rosenblat et al., 2015; Salagre et al., 2017; Vernon et al., 2014).”
BackgroundAn observational treatment study of metacognition in anxious-depression
Fox, C. A., Lee, C. T., Hanlon, A., Seow, T. X. F., Lynch, K., Harty, S., Richards, D., Palacios, J., O'Keane, V., Stephan, K. E., et al. (2023) · doi:10.31234/osf.io/uk7hr · Cited by 2
Metacognition in anxious-depression is state-dependent: an observational treatment study
Fox, C. A., Lee, C. T., Hanlon, A. K., Seow, T. X., Lynch, K., Harty, S., Richards, D., Palacios, J., O’Keane, V., Stephan, K. E., et al. (2023) · doi:10.7554/elife.87193.2 · Cited by 1
Metadata
- Authors
- Vernon, J. A., Grudnikoff, E., Seidman, A. J., Frazier, T. W., Vemulapalli, M. S., Pareek, P., Goldberg, T. E., Kane, J. M., & Correll, C. U.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 159
- Issue
- 2-3
- Pages
- 385-394
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2053874763
- Cited by
- 57
- References
- 11
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.